Lyophilized formulations of tegavivint

1. A pharmaceutical formulation comprising particles of tegavivint or a pharmaceutically acceptable salt thereof; wherein the particles have a median particle diameter D50 of less than or equal to 500 nm and wherein 90% of particles have a diameter D90 of less than or equal to 1.0 micron when measured using laser diffraction, wherein the formulation comprises a poloxamer and one or more stabilizers selected from the group consisting of sucrose, trehalose, and sorbitol, and wherein the formulation is a nanosuspension prepared by a process comprising using either Form I or Form IV polymorph of tegavivint as a starting material and milling the starting material with the poloxamer at a temperature of between about 40° C. and about 60° C.

2. The pharmaceutical formulation of claim 1 , wherein the milling is a ball milling or high energy agitator milling.

3. A lyophilized formulation prepared by a lyophilization process comprising: a) freezing the pharmaceutical formulation of claim 1 ; b) a primary drying step; and c) a secondary drying step.

4. The pharmaceutical formulation of claim 1 , wherein tegavivint concentration is about 25 mg/ml.

5. The pharmaceutical formulation of claim 1 , wherein tegavivint concentration is about 50 mg/ml.

6. The pharmaceutical formulation of claim 1 , wherein the poloxamer is poloxamer 188.

7. The pharmaceutical formulation of claim 1 , wherein the poloxamer concentration is about 6 mg/ml.

8. The pharmaceutical formulation of claim 1 , wherein the poloxamer concentration is about 12.5 mg/ml.

9. The pharmaceutical formulation of claim 1 , wherein the sucrose concentration is about 100 mg/ml.

10. The pharmaceutical formulation of claim 1 , wherein the trehalose concentration is about 100 mg/ml.

11. The pharmaceutical formulation of claim 1 , wherein the sorbitol concentration is about 50 mg/ml.

12. The pharmaceutical formulation of claim 1 , wherein the formulation is autoclaved.

13. The lyophilized formulation of claim 3 , wherein the freezing step is at about −40° C., the primary drying step is at about −30° C. and the secondary drying step is at about −10° C.

14. The pharmaceutical formulation of claim 1 , wherein the formulation is prepared by a ball milling at a temperature of about 60° C.

15. The pharmaceutical formulation of claim 1 , wherein the formulation is prepared by high energy agitator milling at a temperature of about 60° C.

16. The pharmaceutical formulation of claim 1 , wherein the starting material is Form I polymorph of tegavivint.

17. The pharmaceutical formulation of claim 1 , wherein the starting material is Form IV polymorph of tegavivint.

18. The pharmaceutical formulation of claim 1 , wherein the formulation is stable for three months at storage at a temperature of between 5° C. and 25° C.

19. The pharmaceutical formulation of claim 1 , wherein the formulation is stable for six months at storage at a temperature of between 5° C. and 25° C.

20. The pharmaceutical formulation of claim 1 , wherein the formulation is stable for twelve months at storage at a temperature of between 5° C. and 25° C.

21. The pharmaceutical formulation of claim 1 , wherein the formulation is stable for at least eighteen months at storage at a temperature of between 5° C. and 25° C.

22. A method for treating a cancer or tumor metastasis in a mammal in need thereof comprising administering to said mammal an effective amount of the pharmaceutical formulation according to claim 1 .

23. The method of claim 22 , wherein the cancer is acute myeloid leukemia.

24. A reconstituted formulation of tegavivint prepared from the lyophilized formulation of claim 3 , wherein the tegavivint in the reconstituted formulation consists of Form I polymorph of tegavivint.

25. A method for treating a cancer or tumor metastasis in a mammal in need thereof comprising administering to said mammal an effective amount of the reconstituted formulation according to claim 24 .

26. The method of claim 25 , wherein the cancer is acute myeloid leukemia.